These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35184376)

  • 1. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
    Lee CF; Chen YA; Hernandez E; Pong RC; Ma S; Hofstad M; Kapur P; Zhau H; Chung LW; Lai CH; Lin H; Lee MS; Raj GV; Hsieh JT
    Clin Transl Med; 2022 Feb; 12(2):e695. PubMed ID: 35184376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 3.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
    Liu S; Alabi BR; Yin Q; Stoyanova T
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):57-68. PubMed ID: 35597438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
    Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
    Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
    Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
    Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
    Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
    Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
    Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.
    Dayon A; Brizuela L; Martin C; Mazerolles C; Pirot N; Doumerc N; Nogueira L; Golzio M; Teissié J; Serre G; Rischmann P; Malavaud B; Cuvillier O
    PLoS One; 2009 Nov; 4(11):e8048. PubMed ID: 19956567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A; Albino D; Catapano CV; Carbone GM
    Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
    Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
    J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.
    Bhagirath D; Liston M; Akoto T; Lui B; Bensing BA; Sharma A; Saini S
    Sci Rep; 2021 Apr; 11(1):8279. PubMed ID: 33859239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-induced neuroendocrine prostate cancer and
    Wishahi M
    World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
    Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
    J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
    DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
    Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
    Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Front Immunol; 2021; 12():622001. PubMed ID: 33737929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
    Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.